Renaissance Technologies LLC Acquires 36,320 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Renaissance Technologies LLC grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 17.2% in the 4th quarter, Holdings Channel.com reports. The fund owned 247,743 shares of the biopharmaceutical company’s stock after purchasing an additional 36,320 shares during the period. Renaissance Technologies LLC’s holdings in Regeneron Pharmaceuticals were worth $176,475,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. Willner & Heller LLC raised its position in Regeneron Pharmaceuticals by 3.9% during the 4th quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company’s stock worth $284,000 after purchasing an additional 15 shares during the last quarter. OLD Second National Bank of Aurora increased its stake in shares of Regeneron Pharmaceuticals by 0.5% in the fourth quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company’s stock valued at $2,025,000 after buying an additional 15 shares during the period. Rakuten Securities Inc. raised its position in shares of Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 15 shares during the last quarter. TD Private Client Wealth LLC lifted its stake in shares of Regeneron Pharmaceuticals by 9.6% in the fourth quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company’s stock worth $122,000 after acquiring an additional 15 shares during the period. Finally, Manchester Capital Management LLC boosted its holdings in Regeneron Pharmaceuticals by 12.6% in the fourth quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company’s stock valued at $115,000 after acquiring an additional 18 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Bank of America restated an “underperform” rating and issued a $565.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Piper Sandler lowered their price objective on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research report on Monday, January 27th. Bernstein Bank cut their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. UBS Group downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. Finally, Citigroup cut their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $966.88.

Regeneron Pharmaceuticals Trading Down 0.1 %

Shares of REGN stock opened at $572.78 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $557.83 and a 12-month high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a 50 day moving average of $674.46 and a 200-day moving average of $772.53. The firm has a market cap of $62.62 billion, a P/E ratio of 14.96, a PEG ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company’s revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $11.86 earnings per share. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.61%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.